Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2018 1
2019 3
2020 2
2021 4
2022 7
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Childhood Acute Lymphoblastic Leukemia"
Page 1
Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S, Anwar MY, Khalid F, Khan SI, Ali MA, Khattak ZE. Aamir S, et al. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e334-e347. doi: 10.1016/j.clml.2020.12.010. Epub 2020 Dec 17. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33573914
Acute lymphoblastic leukemia (ALL) typically responds better when treated with multiagent chemotherapy in the pediatric and young adolescent populations. Treatment of relapsed/refractory (RR) ALL remains a challenge. Even after stem-cell transpl …
Acute lymphoblastic leukemia (ALL) typically responds better when treated with multiagent chemotherapy in the pediatric …
Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, Daugaard M, Presseau J, Thavorn K, Hutton B, Holt RA, Lalu MM. Grigor EJM, et al. Transfus Med Rev. 2019 Apr;33(2):98-110. doi: 10.1016/j.tmrv.2019.01.005. Epub 2019 Feb 14. Transfus Med Rev. 2019. PMID: 30948292 Free article.
Promising efficacy results of chimeric antigen receptor (CAR) T-cell therapy have been tempered by safety considerations. Our objective was to comprehensively summarize the efficacy and safety of CAR-T cell therapy in patients with relapsed or refractory hema …
Promising efficacy results of chimeric antigen receptor (CAR) T-cell therapy have been tempered by safety considerations. Our objecti …
Patient-Level Meta-analysis of Clofarabine in Acute Lymphoblastic Leukemia.
Jeha S, Goto H, Baruchel A, Boëlle-Le Corfec E, Geffriaud-Ricouard C, Pieters R, Shin HY. Jeha S, et al. Adv Ther. 2023 Dec;40(12):5447-5463. doi: 10.1007/s12325-023-02696-7. Epub 2023 Oct 11. Adv Ther. 2023. PMID: 37819554 Free PMC article.
INTRODUCTION: Clofarabine monotherapy at a dose of 52 mg/m(2) per day was approved in the USA in 2004 for the treatment of relapsed or refractory acute lymphoblastic leukemia (R/R ALL) in patients aged 1-21 years after at least two prior regimens. ...
INTRODUCTION: Clofarabine monotherapy at a dose of 52 mg/m(2) per day was approved in the USA in 2004 for the treatment of relapsed or re …
A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells.
Fergusson NJ, Adeel K, Kekre N, Atkins H, Hay KA. Fergusson NJ, et al. Front Immunol. 2023 Apr 27;14:1178403. doi: 10.3389/fimmu.2023.1178403. eCollection 2023. Front Immunol. 2023. PMID: 37180149 Free PMC article.
Chimeric antigen receptor (CAR) T-cells are an emerging therapy for the treatment of relapsed/refractory B-cell malignancies. While CD19 CAR-T cells have been FDA-approved, CAR T-cells targeting CD22, as well as dual-targeting CD19/CD22 CAR T-cells, are currently be …
Chimeric antigen receptor (CAR) T-cells are an emerging therapy for the treatment of relapsed/refractory B-cell malignancies. …
A systematic review on the cost-effectiveness assessment of tisagenlecleucel for refractory or relapsing B-cell acute lymphoblastic leukemia (R/R B-ALL) treatment in children and young adults.
Andrade AM, Teixeira VR, Pogue R, Figueiredo ACMG, Carvalho JL. Andrade AM, et al. Cytotherapy. 2023 Sep;25(9):930-938. doi: 10.1016/j.jcyt.2023.05.011. Epub 2023 Jun 20. Cytotherapy. 2023. PMID: 37341664
BACKGROUND AIMS: The advanced therapy product tisagenlecleucel is a CD19-directed genetically modified autologous T-cell immunotherapy that has brought hope for children and young adults with relapsed/refractory (R/R) B-cell acute lymphoblastic …
BACKGROUND AIMS: The advanced therapy product tisagenlecleucel is a CD19-directed genetically modified autologous T-cell immunotherap …
Efficacy and Safety of Blinatumomab for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Systemic Review and Meta-Analysis.
Liu H, Xi R, Mao D, Zhao X, Wu T. Liu H, et al. Clin Lymphoma Myeloma Leuk. 2023 Mar;23(3):e139-e149. doi: 10.1016/j.clml.2022.12.009. Epub 2022 Dec 17. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36593170 Review.
OBJECTIVE: The aim was to evaluate the efficacy and safety of blinatumomab monotherapy for the treatment of relapsed/refractory acute lymphoblastic leukemia (R/R B-ALL). METHODS: PubMed, Embase, Web of Science, and Cochrane Library were searched to col …
OBJECTIVE: The aim was to evaluate the efficacy and safety of blinatumomab monotherapy for the treatment of relapsed/refractory ac …
Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
Kathpalia M, Mishra P, Bajpai R, Bhurani D, Agarwal N. Kathpalia M, et al. Ann Hematol. 2022 Aug;101(8):1655-1666. doi: 10.1007/s00277-022-04880-1. Epub 2022 Jun 21. Ann Hematol. 2022. PMID: 35727338 Review.
Nelarabine is approved for the treatment of relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) patients who relapse following at least two different chemotherapy regimens. ...Nelarabine is being used as salvage therapy as a br …
Nelarabine is approved for the treatment of relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia …
Osteoarticular manifestation of acute lymphoblastic leukemia in adults: a literature review.
Slouma M, Hannech E, Ghedira H, Dhahri R, Khrifech Y, Doghri R, Gharsallah I. Slouma M, et al. Clin Rheumatol. 2023 Feb;42(2):607-620. doi: 10.1007/s10067-022-06459-7. Epub 2022 Dec 1. Clin Rheumatol. 2023. PMID: 36454343 Review.
Osteoarticular manifestations such as arthritis and bone pain are scarce among adults with acute lymphoblastic leukemia (ALL). We present a systematic review of osteoarticular first clinical manifestation related to ALL in adults, and we report a case of an a …
Osteoarticular manifestations such as arthritis and bone pain are scarce among adults with acute lymphoblastic leukemia …
Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review.
Becerril-Rico J, Delgado-Montes YA, Ortiz-Sánchez E. Becerril-Rico J, et al. Leuk Lymphoma. 2023 Nov-Dec;64(11):1822-1831. doi: 10.1080/10428194.2023.2243357. Epub 2023 Aug 7. Leuk Lymphoma. 2023. PMID: 37548560
Relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is a challenging disease with low rates of remission and survival in adult patients. ...
Relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is a challenging disease with low rat …
Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
Elsallab M, Ellithi M, Hempel S, Abdel-Azim H, Abou-El-Enein M. Elsallab M, et al. Cancer Gene Ther. 2023 Jun;30(6):845-854. doi: 10.1038/s41417-023-00593-3. Epub 2023 Feb 7. Cancer Gene Ther. 2023. PMID: 36750666 Free PMC article.
Chimeric Antigen Receptor (CAR) T cell therapy is an effective treatment approach for patients with relapsed or refractory acute lymphoblastic leukemia (R/R B-ALL). ...However, further research is needed to optimize patient selection and better …
Chimeric Antigen Receptor (CAR) T cell therapy is an effective treatment approach for patients with relapsed or refractory …
25 results